Michael J Pontecorvo
Overview
Explore the profile of Michael J Pontecorvo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
4751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bocancea D, Svenningsson A, van Loenhoud A, Groot C, Barkhof F, Strandberg O, et al.
Brain
. 2023 Mar;
146(9):3719-3734.
PMID: 36967222
Mechanisms of resilience against tau pathology in individuals across the Alzheimer's disease spectrum are insufficiently understood. Longitudinal data are necessary to reveal which factors relate to preserved cognition (i.e. cognitive...
12.
Kotari V, Southekal S, Navitsky M, Kennedy I, Lu M, Morris A, et al.
Alzheimers Res Ther
. 2023 Mar;
15(1):41.
PMID: 36855201
Background: There is an increasing interest in utilizing tau PET to identify patients early in Alzheimer's disease (AD). In this work, a temporal lobe composite (Eτ) volume of interest (VOI)...
13.
Pontecorvo M, Lu M, Burnham S, Schade A, Dage J, Shcherbinin S, et al.
JAMA Neurol
. 2022 Oct;
79(12):1250-1259.
PMID: 36251300
Importance: Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes. Objective: To analyze the association of donanemab treatment with plasma biomarkers associated with...
14.
Shcherbinin S, Evans C, Lu M, Andersen S, Pontecorvo M, Willis B, et al.
JAMA Neurol
. 2022 Sep;
79(10):1015-1024.
PMID: 36094645
Importance: β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer disease. Objective: To perform post hoc analyses of amyloid reduction after donanemab treatment and assess its association with tau pathology...
15.
Janelidze S, Bali D, Ashton N, Barthelemy N, Vanbrabant J, Stoops E, et al.
Brain
. 2022 Sep;
146(4):1592-1601.
PMID: 36087307
Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays...
16.
Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage J, Pontecorvo M, et al.
Alzheimers Res Ther
. 2022 Jun;
14(1):82.
PMID: 35698175
No abstract available.
17.
Wright J, Goodman J, Lin Y, Lieberman B, Clemens J, Gomez L, et al.
Eur J Nucl Med Mol Imaging
. 2022 May;
49(11):3797-3808.
PMID: 35596745
Purpose: [F]-labeled positron emission tomography (PET) radioligands permit in vivo assessment of Alzheimer's disease biomarkers, including aggregated neurofibrillary tau (NFT) with [F]flortaucipir. Due to structural similarities of flortaucipir with some...
18.
Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage J, Pontecorvo M, et al.
Alzheimers Res Ther
. 2022 May;
14(1):67.
PMID: 35568889
Background: Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer's disease (AD) stages and for monitoring of treatment effects. Plasma measurements of phosphorylated tau...
19.
Tremblay C, Serrano G, Intorcia A, Curry J, Sue L, Nelson C, et al.
J Neuropathol Exp Neurol
. 2022 Feb;
81(3):158-171.
PMID: 35191506
The spread of neurofibrillary tau pathology in Alzheimer disease (AD) mostly follows a stereotypical pattern of topographical progression but atypical patterns associated with interhemispheric asymmetry have been described. Because histopathological...
20.
Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al.
JAMA Neurol
. 2021 Jun;
78(8):961-971.
PMID: 34180956
Importance: Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. Objective: To examine the prognostic...